Stock Analysis on Net

Bristol-Myers Squibb Co. (NYSE:BMY)

Adjustments to Financial Statements

Microsoft Excel

Adjustments to Current Assets

Bristol-Myers Squibb Co., adjusted current assets

US$ in millions

Microsoft Excel
Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
As Reported
Current assets 31,770 27,273 33,262 30,192 29,354
Adjustments
Add: Allowance for expected credit loss 23 22 21 18 21
After Adjustment
Adjusted current assets 31,793 27,295 33,283 30,210 29,375

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).


Adjustments to Total Assets

Bristol-Myers Squibb Co., adjusted total assets

US$ in millions

Microsoft Excel
Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
As Reported
Total assets 95,159 96,820 109,314 118,481 129,944
Adjustments
Add: Operating lease right-of-use asset (before adoption of FASB Topic 842)1
Add: Allowance for expected credit loss 23 22 21 18 21
Less: Deferred income taxes assets, non-current2 2,768 1,344 1,439 1,161 510
After Adjustment
Adjusted total assets 92,414 95,498 107,896 117,338 129,455

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

1 Operating lease right-of-use asset (before adoption of FASB Topic 842). See details »

2 Deferred income taxes assets, non-current. See details »


Adjustments to Total Liabilities

Bristol-Myers Squibb Co., adjusted total liabilities

US$ in millions

Microsoft Excel
Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
As Reported
Total liabilities 65,674 65,702 73,308 80,599 78,246
Adjustments
Add: Operating lease liability (before adoption of FASB Topic 842)1
Less: Deferred income taxes liabilities, non-current2 338 2,166 4,501 5,407 6,454
Less: Restructuring liability 188 47 101 148 100
After Adjustment
Adjusted total liabilities 65,148 63,489 68,706 75,044 71,692

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

1 Operating lease liability (before adoption of FASB Topic 842). See details »

2 Deferred income taxes liabilities, non-current. See details »


Adjustments to Stockholders’ Equity

Bristol-Myers Squibb Co., adjusted total BMS shareholders’ equity

US$ in millions

Microsoft Excel
Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
As Reported
Total BMS shareholders’ equity 29,430 31,061 35,946 37,822 51,598
Adjustments
Less: Deferred tax assets (liabilities), net1 2,430 (822) (3,062) (4,246) (5,944)
Add: Allowance for expected credit loss 23 22 21 18 21
Add: Restructuring liability 188 47 101 148 100
Add: Noncontrolling interest 55 57 60 60 100
After Adjustment
Adjusted total equity 27,266 32,009 39,190 42,294 57,763

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

1 Deferred tax assets (liabilities), net. See details »


Adjustments to Capitalization Table

Bristol-Myers Squibb Co., adjusted capitalization table

US$ in millions

Microsoft Excel
Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
As Reported
Short-term debt obligations 3,119 4,264 4,948 2,340 3,346
Long-term debt, excluding current portion 36,653 35,056 39,605 48,336 43,387
Total reported debt 39,772 39,320 44,553 50,676 46,733
Total BMS shareholders’ equity 29,430 31,061 35,946 37,822 51,598
Total reported capital 69,202 70,381 80,499 88,498 98,331
Adjustments to Debt
Add: Operating lease liability (before adoption of FASB Topic 842)1
Add: Current operating lease liabilities2 162 136 169 164 133
Add: Non-current operating lease liabilities3 1,530 1,261 874 833 672
Adjusted total debt 41,464 40,717 45,596 51,673 47,538
Adjustments to Equity
Less: Deferred tax assets (liabilities), net4 2,430 (822) (3,062) (4,246) (5,944)
Add: Allowance for expected credit loss 23 22 21 18 21
Add: Restructuring liability 188 47 101 148 100
Add: Noncontrolling interest 55 57 60 60 100
Adjusted total equity 27,266 32,009 39,190 42,294 57,763
After Adjustment
Adjusted total capital 68,730 72,726 84,786 93,967 105,301

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

1 Operating lease liability (before adoption of FASB Topic 842). See details »

2 Current operating lease liabilities. See details »

3 Non-current operating lease liabilities. See details »

4 Deferred tax assets (liabilities), net. See details »


Adjustments to Reported Income

Bristol-Myers Squibb Co., adjusted net earnings (loss) attributable to BMS

US$ in millions

Microsoft Excel
12 months ended: Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
As Reported
Net earnings (loss) attributable to BMS 8,025 6,327 6,994 (9,015) 3,439
Adjustments
Add: Deferred income tax expense (benefit)1 (3,288) (2,738) (1,393) 983 (924)
Add: Increase (decrease) in allowance for expected credit loss 1 1 3 (3) (12)
Add: Increase (decrease) in restructuring liability 141 (54) (47) 48 1
Add: Other comprehensive income (loss) (265) (13) 571 (319) 1,242
Add: Comprehensive income (loss), net of tax, attributable to noncontrolling interest 15 18 20 20 21
After Adjustment
Adjusted net earnings (loss) 4,629 3,541 6,148 (8,286) 3,767

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

1 Deferred income tax expense (benefit). See details »